Trichostatin A - Vanda Pharmaceuticals

Drug Profile

Trichostatin A - Vanda Pharmaceuticals

Latest Information Update: 10 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vanda Pharmaceuticals
  • Class Antibacterials; Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 15 Feb 2017 Vanda Pharmaceuticals plans to file an IND application with the FDA in USA for Haematological malignancies
  • 07 Jun 2016 Chemical information added
  • 12 Feb 2016 Vanda Pharmaceuticals has patents pending for Trichostatin A (Vanda Pharmaceuticals 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top